Eaton Vance Management continued to hold its position in shares of DexCom, Inc. (NASDAQ:DXCM) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 69,542 shares of the medical device company’s stock at the end of the second quarter. Eaton Vance Management owned about 0.08% of DexCom worth $5,087,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of the business. Edmond DE Rothschild Holding S.A. acquired a new position in shares of DexCom in the 1st quarter worth approximately $164,000. IFP Advisors Inc raised its holdings in shares of DexCom by 30.5% in the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after buying an additional 568 shares in the last quarter. Independent Portfolio Consultants Inc. raised its holdings in shares of DexCom by 0.4% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after buying an additional 9 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of DexCom by 475.0% in the 1st quarter. Daiwa Securities Group Inc. now owns 2,300 shares of the medical device company’s stock worth $195,000 after buying an additional 1,900 shares in the last quarter. Finally, Accredited Investors Inc. acquired a new position in shares of DexCom in the 1st quarter worth approximately $201,000.
In other DexCom news, EVP Steven Robert Pacelli sold 1,450 shares of the company’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $78.19, for a total transaction of $113,375.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Richard Doubleday sold 1,635 shares of the company’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $75.26, for a total transaction of $123,050.10. Following the sale, the executive vice president now directly owns 72,395 shares in the company, valued at approximately $5,448,447.70. The disclosure for this sale can be found here. In the last three months, insiders sold 26,223 shares of company stock worth $1,881,249. 1.70% of the stock is currently owned by insiders.
DexCom, Inc. (NASDAQ DXCM) opened at 70.29 on Friday. The stock has a 50 day moving average price of $72.47 and a 200 day moving average price of $74.11. The company’s market capitalization is $6.08 billion. DexCom, Inc. has a 52-week low of $57.68 and a 52-week high of $94.79.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The company had revenue of $170.60 million during the quarter, compared to the consensus estimate of $166.54 million. During the same period in the prior year, the business earned ($0.24) earnings per share. The company’s revenue for the quarter was up 24.3% compared to the same quarter last year. Analysts anticipate that DexCom, Inc. will post ($0.77) EPS for the current fiscal year.
A number of equities analysts have recently issued reports on the company. Barclays PLC assumed coverage on DexCom in a report on Friday. They issued an “equal weight” rating and a $76.00 target price for the company. Robert W. Baird reissued a “hold” rating and issued a $79.00 target price on shares of DexCom in a report on Sunday, September 10th. BMO Capital Markets reissued a “buy” rating and issued a $90.00 target price on shares of DexCom in a report on Friday, September 8th. Piper Jaffray Companies reissued an “overweight” rating and issued a $87.00 target price on shares of DexCom in a report on Friday, September 8th. Finally, ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $86.87.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.